Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flavio Vincenti

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
Clinical Transplantation|February 21, 2018
Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXTSander Florman, Flavio Vincenti, Antoine Durrbach, et al.
Transplantation|November 16, 2010
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studiesChristian P Larsen, Josep Grinyó, José Medina-Pestana, et al.
Kidney International|March 4, 2011
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosisHoward Trachtman, Fernando C Fervenza, Debbie S Gipson, et al.
Journal of the American Society of Nephrology : JASN|May 13, 2018
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal TransplantationJulio Pascual, Stefan P Berger, Oliver Witzke, et al.
Transplantation Reviews (Orlando, Fla.)|August 5, 2019
Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patientsJulio Pascual, Stefan P Berger, Steven J Chadban, et al.
Kidney International Reports|December 23, 2017
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental GlomerulosclerosisFlavio Vincenti, Fernando C Fervenza, Kirk N Campbell, et al.
Clinical Transplantation|May 10, 2005
Guidelines for the treatment and management of new-onset diabetes after transplantationAlan Wilkinson, Jaime Davidson, Francesco Dotta, et al.
Journal of the American Society of Nephrology : JASN|July 17, 2010
Five-year safety and efficacy of belatacept in renal transplantationFlavio Vincenti, Gilles Blancho, Antoine Durrbach, et al.
Journal of the American Society of Nephrology : JASN|December 26, 2023
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney TransplantFlavio Vincenti, Oriol Bestard, Amarpali Brar, et al.
Plos Medicine|November 12, 2014
The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART studySilke Roedder, Tara Sigdel, Nathan Salomonis, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Clinical Transplantation|February 21, 2018
Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXTSander Florman, Flavio Vincenti, Antoine Durrbach, et al.
Transplantation|November 16, 2010
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studiesChristian P Larsen, Josep Grinyó, José Medina-Pestana, et al.
Kidney International|March 4, 2011
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosisHoward Trachtman, Fernando C Fervenza, Debbie S Gipson, et al.
Journal of the American Society of Nephrology : JASN|May 13, 2018
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal TransplantationJulio Pascual, Stefan P Berger, Oliver Witzke, et al.
Transplantation Reviews (Orlando, Fla.)|August 5, 2019
Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patientsJulio Pascual, Stefan P Berger, Steven J Chadban, et al.
Kidney International Reports|December 23, 2017
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental GlomerulosclerosisFlavio Vincenti, Fernando C Fervenza, Kirk N Campbell, et al.
Clinical Transplantation|May 10, 2005
Guidelines for the treatment and management of new-onset diabetes after transplantationAlan Wilkinson, Jaime Davidson, Francesco Dotta, et al.
Journal of the American Society of Nephrology : JASN|July 17, 2010
Five-year safety and efficacy of belatacept in renal transplantationFlavio Vincenti, Gilles Blancho, Antoine Durrbach, et al.
Journal of the American Society of Nephrology : JASN|December 26, 2023
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney TransplantFlavio Vincenti, Oriol Bestard, Amarpali Brar, et al.
Plos Medicine|November 12, 2014
The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART studySilke Roedder, Tara Sigdel, Nathan Salomonis, et al.
Pageof 12